FDA Advisory Committee Recommends Johnson & Johnson’s DARZALEX FASPRO® for High-Risk Smoldering Multiple Myeloma
Potentially Groundbreaking Treatment Could Delay or Prevent Progression to Full-Blown Myeloma.
Tag: Johnson&Johnson
Johnson & Johnson Launches MENTOR™ MemoryGel™ Breast Implants for Reconstruction Patients
The creation of these implants is a direct answer to the demands of patients who need primary or revision reconstruction following a mastectomy.
Johnson & Johnson’s Icotrokinra Shows Significant Skin Clearance in Difficult-to-Treat Psoriasis
In a Phase 3 trial, investigational icotrokinra led to 66% of scalp psoriasis patients and 77% of genital psoriasis patients achieving clear or almost clear skin specifically on those affected sites by Week 16.
Data From Phase 3 QUASAR Long-term Extension (LTE) Study Shows TREMFYA® (guselkumab) Maintains Sustained Remission in Ulcerative Colitis
Johnson & Johnson today announced significant long-term findings from the Phase 3 QUASAR study program, demonstrating that TREMFYA® (guselkumab) delivered sustained rates of clinical remission [Read More…]
Johnson & Johnson’s IMAAVY™ (nipocalimab-aahu) Receives U.S. FDA Approval, a Novel FcRn Blocker for Generalized Myasthenia Gravis Patients
IMAAVY demonstrated a swift and significant decrease in IgG levels, a primary driver of gMG, in key adult and pediatric trials.
Johnson & Johnson Discontinued VENTURA Drug Development Program
The Phase 3 VENTURA research study, which was assessing aticaprant as an adjunctive treatment for major depressive disorder (aMDD), has been discontinued by Johnson & [Read More…]
